There are >100 publications in PubMed that report resistance to pemetrexed in lung cancers associated with elevated TYMS levels or sustained benefit from pemetrexed in lung cancers associated with reduced TYMS levels [1]. This evidence concerns the gene TYMS and lung carcinoma.